This is a working overview of Enkephalinase, written for readers who want more than a one-paragraph summary but less than a textbook.
Reviewed 2026-01-25. Anything still debated is marked as such rather than presented as settled.
Published clinical evidence is limited. Most controlled trials were conducted in Russia, enrolled modest numbers of participants, and appeared in Russian-language journals, which restricts independent verification. Reported outcomes include lower anxiety scores, improved attention and memory measures, and changes in fatigue ratings. Reviews written in English note methodological limitations such as small samples and inconsistent endpoints. Whether the compound produces clinically meaningful benefit relative to established anxiolytics is therefore an open question rather than an established finding.
Selank is a synthetic heptapeptide with the sequence Thr-Lys-Pro-Arg-Pro-Gly-Pro. It was designed at the Institute of Molecular Genetics of the Russian Academy of Sciences as a structural analogue of tuftsin, a naturally occurring tetrapeptide fragment of the immunoglobulin heavy chain. The added Pro-Gly-Pro tail was intended to slow enzymatic degradation and extend biological activity. In Russia it is registered as an anxiolytic nasal preparation, while regulators elsewhere have not approved it for clinical use.
Solubility behavior is a practical concern for handling. Selank dissolves readily in water and in common aqueous buffers, which simplifies preparation of working solutions. The choice of solvent, ionic strength, and pH can influence aggregation over time, particularly at higher concentrations. Aqueous solutions are typically sterile-filtered before use. Because stability depends on several variables, storage and handling notes should be treated as general guidance rather than fixed rules, and specific values are best confirmed against a certificate of analysis for each batch.
Characterization of Selank in a laboratory setting relies on standard peptide methods. Reverse-phase high-performance liquid chromatography separates the target from related impurities and provides a purity figure, commonly reported as 95 percent or higher. Mass spectrometry, typically electrospray ionization or matrix-assisted laser desorption, confirms the molecular mass and helps detect truncation or modification. Amino acid analysis can verify composition when a sequence-level check is needed. These techniques together establish identity and purity for a given lot.
Lyophilized Selank, the dry powder form, is generally stored frozen at minus 20 degrees Celsius or colder for long-term keeping. The solid is hygroscopic and should stay sealed, dry, and protected from light. Once dissolved, the peptide is less stable and is usually held refrigerated at 2 to 8 degrees Celsius for short periods. Repeated freezing and thawing is avoided because it can promote aggregation and loss of activity. Buffers and pH choice also affect how long a solution remains usable.
| Property | Value | Notes |
|---|---|---|
| Molecular formula | C33H57N11O9 | Free peptide form |
| Molecular mass | About 751.9 Da | Calculated average mass |
| Amino acid sequence | Thr-Lys-Pro-Arg-Pro-Gly-Pro | Single-letter form TKPRPGP |
| Structural basis | Tuftsin analogue | Extended version of a natural tetrapeptide |
| Development origin | Russian Academy of Sciences | Work carried out from the 1980s onward |
Outside its country of origin the compound is generally handled as a research chemical rather than an approved medicine. No regulatory approval from the United States Food and Drug Administration or the European Medicines Agency has been granted for human use. Identity and purity are normally checked by reverse-phase high-performance liquid chromatography, with mass spectrometry used to confirm the molecular mass. Lyophilised material is stored cold and desiccated, and repeated freeze-thaw cycles are avoided.
Published work on this peptide almost always uses intranasal delivery, with drops or a spray applied to the nasal mucosa. Some animal experiments have used subcutaneous or intraperitoneal injection, and a smaller number have compared routes directly. Oral administration is not a focus of the literature, because short peptides of this size are broken down by digestive enzymes and cross intestinal barriers poorly. How much of an intranasal dose reaches the bloodstream intact in humans remains an open question.
Animal studies have examined behaviour in tests of anxiety, memory retention and stress response, and several report changes in neurotrophic or neurotransmitter-related markers. The human evidence base is much smaller, consisting mainly of short trials conducted in Russia with limited reporting in English-language journals. Sample sizes are modest and outcome measures vary between studies, so the findings are best described as preliminary. Independent replication under modern trial standards has not been widely reported.
Peptide bonds in selank are susceptible to hydrolysis under strongly acidic or basic conditions, and the terminal proline residues are vulnerable to exopeptidase activity in biological samples. Lyophilized powder stored dry at -20 °C typically remains stable for extended periods, whereas aqueous solutions degrade faster and may lose measurable purity within days to weeks depending on pH, temperature, and microbial load. Repeated freeze-thaw cycles promote aggregation and adsorption to container surfaces. For analytical work, solutions are usually prepared fresh, kept cold, and used within a single working day.
Handling follows standard practice for research peptides. Material is weighed in a low-humidity environment because the powder absorbs atmospheric moisture. Purity is reported as the percentage area of the main peak in a chromatogram, with specifications commonly set at 95 percent or higher; values below that threshold indicate the presence of truncated or modified species. Residual trifluoroacetate from purification is often present and may affect mass balance. Certificates of analysis should state the analytical method, the column and gradient used, and the lot-specific retention time so that results can be compared across suppliers.
Identity and purity of selank are established with reversed-phase high-performance liquid chromatography coupled to mass spectrometry. The peptide elutes from C18 columns with acetonitrile gradients in water containing trifluoroacetic acid or formic acid, and detection is usually performed by ultraviolet absorbance near 214 nm. Electrospray ionization in positive mode gives a doubly protonated ion near m/z 377, consistent with a mass of about 752 Da. Amino acid analysis or tandem mass spectrometry of fragment ions confirms the sequence. Because the molecule has no aromatic residues, it lacks a usable 280 nm chromophore, so low-wavelength detection or mass spectrometry is required.
Selank is a synthetic heptapeptide with the sequence Thr-Lys-Pro-Arg-Pro-Gly-Pro, written TKPRPGP in one-letter notation. Its structure consists of the immunomodulatory tetrapeptide tuftsin, Thr-Lys-Pro-Arg, extended at the carboxyl terminus by a Pro-Gly-Pro segment. The molecular formula is commonly given as C33H57N11O9, corresponding to a monoisotopic mass near 751.4 Da and an average molecular mass near 751.9 Da. All seven residues are proteinogenic amino acids, and the molecule carries no modified side chains or non-natural linkages.
The compound was designed at the Institute of Molecular Genetics of the Russian Academy of Sciences during the 1980s and 1990s. The stated design goal was to retain the immunomodulatory and central nervous system activity attributed to tuftsin while improving resistance to enzymatic breakdown. Adding a proline-rich tail to the short parent peptide was a deliberate strategy, because proline residues restrict the conformations available to many peptidases. The same laboratory produced Semax, an ACTH fragment analog, and both compounds were developed in parallel as short, enzymatically stabilized peptides intended for intranasal use.
He also vetoed the "Green Giant", a skyscraper on the South Bank, initiated plans for the National Gallery extension (the winning entry was famously described by Prince Charles as "a monstrous carbuncle" and was never built) and signed off on the building of the Queen Elizabeth II Centre on a bomb site near Westminster; when he was unable to secure private funding as planned the Treasury were forced to pay for the building. Some of the DoE's responsibilities were hived off into English Heritage, a new body.
=== Mortality === Mortality is increased in people with AS and circulatory disease is the most frequent cause of death. People with AS have an increased risk of 60% for cerebrovascular mortality, and an overall increased risk of 50% for vascular mortality. About one third of those with ankylosing spondylitis have severe disease, which reduces life expectancy. As increased mortality in ankylosing spondylitis is related to disease severity, factors negatively affecting outcomes include:
With the exception of Russia, the Polish nation has the distinction among other Slavic peoples of having enjoyed independence as a part of various entities for several centuries prior to the advent of Pan-Slavism. After 1795, Revolutionary and Napoleonic France had influenced many Poles who sought the reconstitution of their existing country—particularly since France was a mutual enemy of Austria, Prussia, and also Russia. Russia's Pan-Slavic rhetoric had alarmed the Poles. Pan-Slavism was not fully embraced among Poles after the early period. Poland did nevertheless express solidarity with those of its fellow Slavic nations that had suffered oppression and were seeking independence. While Pan-Slavism as an ideology was inimical to Austro-Hungarian interests, Poles instead embraced the wide autonomy within the state and assumed a loyalist position towards the Habsburgs. Within the Austro-Hungarian polity, they were able to develop their national culture and preserve the Polish language, both of which were under threat in both German and Russian Empires. A Pan-Slavic federation was proposed, but on the condition that the Russian Empire would be excluded from such an entity. After Poland regained its independence (from Germany, Austria and Russia) in 1918, no internal faction considered Pan-Slavism as a serious alternative, viewing Pan-Slavism as Russification. During Poland's communist era, the USSR used Pan-Slavism as a propaganda tool to justify its control over the country.
He sailed for New York on the RMS Caronia on 19 September 1925, intending to study under Robert Chambers at Cornell University Medical College, but the micromanipulator he required for his research on the blood vessels of the brain was not available, so he arranged to work at the laboratory of Alfred Newton Richards at the University of Pennsylvania. He finally joined Chambers in March 1926. He hoped to be able to return to the UK via Australia and marry Ethel Reed in Adelaide, but in November 1925 he accepted an offer of a research position at London Hospital. The position came with five years' tenure and a salary of £850 per annum (equivalent to £45,000 in 2025), but they wanted him to start immediately. Florey managed to negotiate a delay, but only until May 1926. He returned to the UK on 13 May. Ethel joined him there in September, and they were married at Holy Trinity, Paddington, on 19 October.
Andexanet alfa is a biologic agent, a recombinant modified version of human activated factor X (FXa). Andexanet alfa differs from native FXa due to the removal of a 34 residue fragment that contains the Gla domain. This modification reduces andexanet alfa's anticoagulant potential. Additionally, a serine to alanine (S419A) mutation in the active site eliminates its activity as a prothrombin to thrombin catalyst, but still allows the molecule to bind to FXa inhibitors. FXa inhibitors bind to andexanet alfa with the same affinity as to natural FXa. As a consequence, in the presence of andexanet alfa, natural FXa is partially freed, which can lead to effective hemostasis. In other words, it acts as a decoy receptor. Andexanet alfa reverses effect of all anticoagulants that act directly through FXa or by binding antithrombin III. The drug is not effective against factor IIa inhibitor dabigatran. Its activity is measured using the anti-Xa test, which is utilized to determine the amount of available factor Xa for coagulation
Sources: en.wikipedia.org
When an 235U atom captures a neutron, it is converted to an excited state of 236U. About 85.5% of the excited 236U nuclei undergo fission, but the remainder decay to the ground state of 236U by emitting gamma radiation. Further neutron capture forms 237U which has a half-life of 7 days and quickly decays to 237Np through beta decay. During beta decay, the excited 237U emits an electron, while the atomic weak interaction converts a neutron to a proton, thus creating 237Np.
Tin-121m (121mSn) is a nuclear isomer of tin with a half-life of 43.9 years, making it technically a medium-lived fission product. In a normal thermal reactor, it has a very low fission product yield; thus, this isotope is not a significant contributor to nuclear waste. Fast fission or fission of some heavier actinides will produce it at higher yields. For example, its yield from uranium-235 is 0.0007% per thermal fission and 0.002% per fast fission.
In both cases, Oedipus can therefore be recognized as a "liminal" or threshold figure, helping effect the transition between the old religious practices, represented by the death of the Sphinx, and the rise of the new, Olympian gods.
Adipocytes, also known as lipocytes and fat cells, are the cells that primarily compose adipose tissue, specialized in storing energy as fat. Adipocytes are derived from mesenchymal stem cells which give rise to adipocytes through adipogenesis. In cell culture, adipocyte progenitors can also form osteoblasts, myocytes and other cell types. There are two types of adipose tissue, white adipose tissue (WAT) and brown adipose tissue (BAT), which are also known as white and brown fat, respectively, and comprise two types of fat cells.
=== Countercurrent exchange in sea and desert birds to conserve water === Sea and desert birds have been found to have a salt gland near the nostrils which concentrates brine, later to be "sneezed" out to the sea, in effect allowing these birds to drink seawater without the need to find freshwater resources. It also enables the seabirds to remove the excess salt entering the body when eating, swimming or diving in the sea for food. The kidney cannot remove these quantities and concentrations of salt. The salt secreting gland has been found in seabirds like pelicans, petrels, albatrosses, gulls, and terns. It has also been found in Namibian ostriches and other desert birds, where a buildup of salt concentration is due to dehydration and scarcity of drinking water. In seabirds the salt gland is above the beak, leading to a main canal above the beak, and water is blown from two small nostrils on the beak, to empty it. The salt gland has two countercurrent mechanisms working in it: a. A salt extraction system with a countercurrent multiplication mechanism, where salt is actively pumped from the blood 'venules' (small veins) into the gland tubules. Although the fluid in the tubules is with a higher concentration of salt than the blood, the flow is arranged in a countercurrent exchange, so that the blood with a high concentration of salt enters the system close to where the gland tubules exit and connect to the main canal.
Sources: en.wikipedia.org
Marlowe (1988), creator of Castle; writer of Air Force One, End of Days, and Hollow Man Lawrence Trilling (1988), showrunner of Parenthood and Goliath Maiken Baird (1989), documentary film producer, Client 9: The Rise and Fall of Eliot Spitzer Sam Bisbee (1990), Emmy Award-winning producer and composer Gina Fattore (1990), producer and writer of Dawson's Creek, Gilmore Girls, Parenthood, creator of Dare Me Jeff Rake (1990), television producer, writer of Boston Legal and creator of Manifest and The Mysteries of Laura Dede Gardner (1990), Academy Award-winning producer of 12 Years a Slave; president of Plan B Entertainment Jenji Kohan (1991), television writer, producer, creator of Orange Is the New Black and Weeds Ari Gold (1992), filmmaker, director of Adventures of Power Elizabeth Craft (1993), producer, screenwriter, Fantasy Island, The 100, Lie to Me Ethan McSweeny (1993), former artistic director of the American Shakespeare Center, recipient of a 2018 Helen Hayes Award Brian Yorkey (1993), playwright, co-winner of the 2010 Pulitzer Prize for Drama for writing the musical Next to Normal Anna Winger (1993), screenwriter, creator of miniseries Deutschland 83, Deutschland 86, and Unorthodox Imara Jones (1994), political journalist and director Nicole Kassell (1994), director and producer of Watchmen, winner of the 2020 Directors Guild of America Award for Outstanding Directing – Drama Series Tim Carvell (1995), head writer of The Daily Show and executive producer of Last Week Tonight with John Oliver Josh Fox (1995), Academy Award-nominated documentary director, Gasland Adam Egypt Mortimer (1995), director of Daniel Isn't Real, Archenemy Henry Alex Rubin (1995), Academy Award-nominated director, Murderball Julius Sharpe (1995), television writer and showrunner of Making History and United We Fall Ramin Bahrani (1996), writer-director of Man Push Cart, Chop Shop and Fahrenheit 451, 2021 Academy Award for Best Adapted Screenplay nominee Moira Demos (1996), filmmaker who produced Netflix documentary Making a Murderer Yana Gorskaya (1996), Academy Award-nominated film editor, Spellbound Cetywa Powell (1996), director and fine art photographer Courtney Lilly (1997), television producer, showrunner of Black-ish, Grown-ish, Mixed-ish Nancy Schwartzman (1997), director, Roll Red Roll Beau Willimon (1999), creator and producer of House of Cards; writer of the play Farragut North Vikram Gandhi (2000), director, Kumaré, Barry, reporter for Vice Andrew Goldberg (2000), creator of Netflix series Big Mouth Ned Benson (2001), director, The Disappearance of Eleanor Rigby Dan Harris (2001), Saturn Award-winning screenwriter, X2, Superman Returns; director, Imaginary Heroes Andrew Neel (2001), filmmaker, director of King Kelly, Goat Anna Boden (2002), co-writer of Half Nelson and director of Sugar, Captain Marvel Tze Chun (2002), award-winning director, Children of Invention Lang Fisher (2002), co-creator of Never Have I Ever, writer of 30 Rock and Brooklyn Nine-Nine, Peabody Award winner in 2008 Susanna Fogel (2002), Emmy Award and BAFTA Award-nominated director Will Graham (2002), creator of the Onion News Network, showrunner of Mozart in the Jungle, Peabody Award winner in 2008 Ashley Lyle (2002), screenwriter, showrunner of Yellowjackets Justin Marks (2002), screenwriter, The Jungle Book, Counterpart Katori Hall (2003), playwright, The Mountaintop, winner of the 2021 Pulitzer Prize for Drama Raamla Mohamed (2003), Emmy Award-nominated screenwriter, Little Fires Everywhere Graham Moore (2003), winner of the 2015 Academy Award for Best Adapted Screenplay for his screenplay of The Imitation Game Lucia Aniello (2004), director of Rough Night and Time Traveling Bong Gabe Liedman (2004), creator of Q-Force, writer of Brooklyn Nine-Nine, PEN15, Inside Amy Schumer and Kroll Show Zhang Mo (2005), Chinese director, daughter of Zhang Yimou Laura Goode (2006), author, columnist, and producer of Farah Goes Bang Matt Kaplan (2006), producer of young adult films, To All the Boys franchise Meera Menon (2006), Indian-American director, Equity Lilly Burns (2009), television producer, co-founder of Jax Media and president of Imagine Entertainment Eli Bush (2009), film and theatre producer and winner of the Golden Globe Award in 2018 for Lady Bird Jason Fuchs (2009), actor and screenwriter, Pan, Ice Age: Continental Drift Jessica Kingdon (2009), Academy Award-nominated Chinese-American documentary director Nuotama Bodomo (2010), Ghanaian filmmaker and co-writer of sketch comedy Random Acts of Flyness on HBO Sabaah Folayan (2013), director of documentary Whose Streets?
=== Incubator Lab Facility Investment === When SHIELD Illinois consolidated its labs into two University-owned and operated facilities to optimize logistics during the 2021-2022 school year. The Incubator Lab Facility on the University of Illinois Chicago (UIC) campus, the building where SHIELD Illinois's NextGen sequencing and innovation lab was located, was not originally built to meet the criteria of a CLIA-certified clinical diagnostics lab. So, the program decided to invest in upgrading the facility to bring it up to modern standards. According to Len Musielak, SHIELD Illinois Senior Director of Operations, SHIELD wanted to not only upgrade the building for its purposes but also add in ways that would provide a benefit to other tenants now and far into the future. The project included $2.2 million in upgrades and had a six-week deadline to complete the most difficult tasks and make the lab operational. Facility upgrades included:
=== Metabolic disorders === Opioids are primarily metabolized in the liver, before being excreted through urine. Opioids are metabolized by phase 1 and/or phase 2 metabolism, which can lead to the activation or inhibition of these drugs. Phase 1 metabolism is the CYP pathway which consists of different cytochrome P450s – a set of enzymes that catalyze hydrolysis, reduction, and oxidation reactions – to create an active metabolite. In contrast, Phase 2 metabolism causes the opioids to undergo conjugation, with little to no interaction with the CYP pathway. The opioids undergo phase 1 and phase 2 metabolism until they are hydrophilic enough to be renally excreted. Various factors play a role in how an opioid is metabolized. In phase 1 metabolism, the CYP family has several polymorphisms, which can account for the difference in therapeutic responses within each individual. This diversification leads to opioids being modified at varying rates, which can cause the drug to remain in the bloodstream for either a longer or shorter period. Therefore, these polymorphisms control opioid tolerance and facilitate overdose.
Moxetumomab pasudotox, sold under the brand name Lumoxiti, is an anti-CD22 immunotoxin medication for the treatment of adults with relapsed or refractory hairy cell leukemia (HCL) who have received at least two prior systemic therapies, including treatment with a purine nucleoside analog. Moxetumomab pasudotox is a CD22-directed cytotoxin and is the first of this type of treatment for adults with HCL. The drug consists of the binding fragment (Fv) of an anti-CD22 antibody fused to a toxin called PE38. This toxin is a 38 kDa fragment of Pseudomonas exotoxin A. Hairy cell leukemia (HCL) is a rare, slow-growing cancer of the blood in which the bone marrow makes too many B cells (lymphocytes), a type of white blood cell that fights infection. HCL is named after these extra B cells which look “hairy” when viewed under a microscope. As the number of leukemia cells increases, fewer healthy white blood cells, red blood cells and platelets are produced.
Sources: en.wikipedia.org
It is a seven-amino-acid peptide, Thr-Lys-Pro-Arg-Pro-Gly-Pro, produced by chemical synthesis rather than extracted from biological tissue. Its design is based on tuftsin, a natural immunomodulatory tetrapeptide. The C-terminal Pro-Gly-Pro segment is a common stabilising motif in short regulatory peptides.
The core four residues correspond to tuftsin, which occurs naturally as part of immunoglobulin G. The full seven-residue sequence, however, is not a known endogenous peptide. It is a laboratory-designed analogue intended to combine tuftsin-like activity with greater resistance to breakdown.
No single receptor has been confirmed as the primary target. Reports describe involvement of the GABAergic system, interference with enkephalin degradation, and shifts in neurotrophic factor expression. Because these observations come from different models and assays, they have not yet been integrated into one accepted mechanism.
Reverse-phase HPLC is the usual method and gives a percentage purity value. Mass spectrometry then confirms the molecular mass. Together they provide a basic identity and purity profile for a lot.